Market Place
Sourcing Support
Evofem Biosciences Announces Financial Results for the Q3 of 2024
14 Nov 2024 //
PR NEWSWIRE
NeoGenomics Launches AML Express For Rapid Genetic Profiling
08 Oct 2024 //
BUSINESSWIRE
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
03 Oct 2024 //
BUSINESSWIRE
Evofem Biosciences Files Proxy for Aditxt Acquisition Approval
24 Sep 2024 //
BUSINESSWIRE
Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem
20 Sep 2024 //
BUSINESSWIRE
Aditxt-Evofem Merger Set To Close In Q4 2024
09 Sep 2024 //
BUSINESSWIRE
Evofem Biosciences Announces Financial Results for the Second Quarter of 2024
14 Aug 2024 //
PR NEWSWIRE
Aditxt And Evofem Amend Merger Agreement, Target September 30 Closing
17 Jul 2024 //
BUSINESSWIRE
Lupin Divests US Women`s Health Specialty Business To Evofem
15 Jul 2024 //
PR NEWSWIRE
Lupin divests women’s health specialty business in US to Evofem for $84 million
15 Jul 2024 //
MONEY CONTROL
Evofem Biosciences receives new US patent covering Phexxi composition of matter
12 Jun 2024 //
PHARMABIZ
In $100M deal, troubled Evofem sells itself to Aditxt
12 Dec 2023 //
FIERCE PHARMA
FDA accuses Evofem of overstating efficacy of contraceptive gel
10 Nov 2023 //
FIERCE PHARMA
FDA watchdog admonishes Evofem for marketing brochure for contraceptive Phexxi
08 Nov 2023 //
ENDPTS
Evofem to Participate in the Virtual Investor Ask the CEO Conference
13 Oct 2023 //
PR NEWSWIRE
Evofem Biosciences Successfully Amends S.P.A. with Institutional Investor
11 Sep 2023 //
PR NEWSWIRE
Evofem Signs Letter of Intent to Enable Listing on a National Stock Exchange
22 Aug 2023 //
PR NEWSWIRE
Evofem Biosciences Announces Financial Results for the Second Quarter of 2023
14 Aug 2023 //
PR NEWSWIRE
Evofem to Participate in the Virtual Investor Summer Spotlight Series
06 Jul 2023 //
PR NEWSWIRE
Evofem Biosciences Announces Financial Results for the First Quarter of 2023
16 Jun 2023 //
PR NEWSWIRE
Evofem Biosciences Announces Strong Preliminary Results for Q1 of 2023
01 Jun 2023 //
PR NEWSWIRE
Evofem Biosciences Announces 1-for-125 Reverse Stock Split
17 May 2023 //
PR NEWSWIRE
Evofem Appoints Ivy Zhang as Chief Financial Officer and Secretary
14 Apr 2023 //
PR NEWSWIRE
Evofem Biosciences Announces Cost Reduction Measures
21 Mar 2023 //
PR NEWSWIRE
Evofem makes top-to-bottom cuts, slashing CEO pay by 40%
21 Mar 2023 //
FIERCE BIOTECH
Evofem Biosciences Appoints Interim Chief Financial Officer
09 Mar 2023 //
PR NEWSWIRE
Contraceptive gel maker Evofem kicks off strategic review
24 Feb 2023 //
FIERCE PHARMA
Evofem`s Phexxi Contraceptive Gel to be Offered by Female Leader Favor
12 Jan 2023 //
PR NEWSWIRE
Evofem`s approved birth control gel flops PhIII for STI prevention
13 Oct 2022 //
ENDPTS
Evofem Biosciences Announces Approval of Phexxi in Nigeria
06 Oct 2022 //
PRNEWSWIRE
Evofem Biosciences Announces Uplisting to OTCQB
03 Oct 2022 //
PRNEWSWIRE
Evofem Biosciences receives US patent covering Phexxi composition of matter
26 Sep 2022 //
PHARMABIZ
Evofem Announces Issuance of U.S. Patent Covering Phexxi® Composition of Matter
23 Sep 2022 //
PRNEWSWIRE
Large Commercial Payer Adds Phexxi® to Formulary for Standard Plans Nationwide
16 Sep 2022 //
PRNEWSWIRE
Evofem Announces Successful Debt Restructuring
16 Sep 2022 //
PRNEWSWIRE
Evofem Completes LSLV in Registrational PIII "EVOGUARD" Trial Evaluating Phexxi
01 Aug 2022 //
PRNEWSWIRE
Evofem Biosciences to Report Second Quarter 2022 Results
28 Jul 2022 //
PRNEWSWIRE
Phexxi MOA Article Published in Journal of Therapeutic Advances
12 Jul 2022 //
PRNEWSWIRE
Evofem Strengthens Phexxi IP with New Composition of Matter Patent From USPTO
30 Jun 2022 //
PRESS RELEASE
Evofem Reaches Agreement with One of the Largest Pharmacy Benefit Managers
28 Jun 2022 //
PRNEWSWIRE
Phexxi Prevented 99% of Pregnancies Per Act of Intercourse in PIII Trial Data
16 Jun 2022 //
PRNEWSWIRE
US Food and Drug Administration Extends Phexxi® Shelf Life to Four Years
02 Jun 2022 //
PRNEWSWIRE
Evofem Biosciences Announces Proposed Public Offering
19 May 2022 //
PRNEWSWIRE
Evofem’s Phase III trial reveals fewer UTIs in women using Phexxi
09 May 2022 //
PHARMAFILE
Evofem Presents Data Detailing Fewer Urinary Tract Infections in Women
06 May 2022 //
PRNEWSWIRE
Evofem Biosciences Announces 1-for-15 Reverse Stock Split
05 May 2022 //
PRNEWSWIRE
Evofem Biosciences Reports First Quarter 2022 Financial Results
04 May 2022 //
PRNEWSWIRE
Evofem to Present New Research in Gynecological Health at the 2022 ACOG
26 Apr 2022 //
PRNEWSWIRE
Journal of Sexual Medicine Publishes Data Involving Phexxi from PIII Trial
19 Apr 2022 //
PRNEWSWIRE
Evofem Announces Karina Fedasz as Company`s New Head of Business Development
11 Apr 2022 //
PRNEWSWIRE
Evofem Biosciences Reports Fourth Quarter and Year-End 2021 Financial Results
03 Mar 2022 //
PRNEWSWIRE
Evofem Bio Announces Record Net Sales and Phexxi Prescriptions in Q4 2021
19 Jan 2022 //
PRNEWSWIRE
Evofem Biosciences, Orion Biotechnology Enter OB-002 Alliance
20 Dec 2021 //
CONTRACTPHARMA
Evofem does Regulatory Submission in Mexico for Its Hormone-Free Contraceptive
10 Nov 2021 //
PRNEWSWIRE
"House Rules" Delivers Strong Initial Results and Drives Phexxi Growth
20 Oct 2021 //
PRNEWSWIRE
Evofem Biosciences Announces $10 Million Registered Direct Offering of Series B
12 Oct 2021 //
PRNEWSWIRE
Early Look at Second Quarter Metrics for Phexxi® Reveals Strong Growth
14 Jul 2021 //
PRNEWSWIRE
Early Look at Second Quarter Metrics for Phexxi® Reveals Strong Growth
14 Jul 2021 //
PRNEWSWIRE
Evofem Biosciences Announces Pricing of $50 Million Public Offering
18 May 2021 //
PRNEWSWIRE
